Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary HIV Infection.

Joanne Stekler1, Ann C Collier

  • 1Department of Medicine, Harborview Medical Center, Seattle, WA 98104, USA. jstekler@u.washington.edu

Current HIV/AIDS Reports
|August 11, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antigen specificities and proviral integration sites differ in HIV-infected cells by timing of antiretroviral treatment initiation.

The Journal of clinical investigation·2024
Same author

Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trial.

AIDS (London, England)·2024
Same author

The immunogenicity of an HIV-1 Gag conserved element DNA vaccine in people with HIV and receiving antiretroviral therapy.

AIDS (London, England)·2023
Same author

A novel formulation enabled transformation of 3-HIV drugs tenofovir-lamivudine-dolutegravir from short-acting to long-acting all-in-one injectable.

AIDS (London, England)·2023
Same author

Buy or Build: Challenges Developing Consumer Digital Health Interventions.

Applied clinical informatics·2023
Same author

U.S. patient preferences for long-acting HIV treatment: a discrete choice experiment.

Journal of the International AIDS Society·2023
Same journal

IAS 2025: Why Can't I Breastfeed My Baby When Evidence and Lived Experience Say I Can? A Call for Policy Equity for Mothers Living with HIV.

Current HIV/AIDS reports·2026
Same journal

Cytomegalovirus and HIV Co-Infections During Pregnancy and Early Childhood.

Current HIV/AIDS reports·2026
Same journal

HIV Reservoirs in Brain parenchyma and Cerebrospinal Fluid During Suppressive ART: Same-Same or Very Different?

Current HIV/AIDS reports·2026
Same journal

HIV-1 Tat-driven Glutamate Dysregulation: Implications for Cognitive Impairment in HAND.

Current HIV/AIDS reports·2026
Same journal

Central Nervous System HIV Persistence and Clinical Consequences During Suppressive ART.

Current HIV/AIDS reports·2026
Same journal

Expanding PrEP Access Through Decentralized Delivery Models.

Current HIV/AIDS reports·2026
See all related articles

Early treatment for primary HIV infection may lower viral set point and preserve immune function, though benefits require further study. Resistance testing before therapy is recommended for HIV management.

Area of Science:

  • Infectious Diseases
  • Virology
  • Immunology

Background:

  • Primary HIV infection is the initial stage following HIV acquisition, often presenting with nonspecific symptoms in 40-90% of individuals.
  • Patients identified pre-seroconversion typically exhibit high plasma HIV RNA levels, eventually stabilizing at a viral set point without treatment.
  • Current highly active antiretroviral therapy (HAART) does not prevent chronic HIV infection establishment.

Purpose of the Study:

  • To explore the potential benefits of very early antiretroviral therapy during primary HIV infection.
  • To assess if early intervention can decrease the viral set point, prevent viral diversification, and preserve immune function.
  • To evaluate the impact of early therapy on clinical outcomes and secondary HIV transmission.

Main Methods:

Related Experiment Videos

  • Observational analysis of patients during primary HIV infection.
  • Review of treatment strategies including highly active antiretroviral therapy (HAART).
  • Consideration of resistance testing and adjuvant therapies like immunomodulators and vaccines.

Main Results:

  • Treatment of primary HIV infection with HAART does not prevent chronic infection.
  • Potential benefits of very early therapy, such as lowering viral set point and preserving immunity, are not definitively proven.
  • Drug-resistant HIV strains necessitate resistance testing before initiating therapy in primary infection.

Conclusions:

  • While early HAART may offer theoretical advantages in primary HIV infection, definitive clinical benefits remain to be demonstrated.
  • Resistance testing is crucial for guiding therapy in primary HIV infection due to the risk of transmitting drug-resistant strains.
  • Further research into adjuvant therapies, including immunomodulators and vaccines, is ongoing for primary HIV infection management.